European Price Controls Will Erode Immunotherapy Viability
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
07 Aug 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$24.93
30.8% overvalued intrinsic discount16 Aug
US$32.59
1Y
-11.7%7D
0.9%